血小板因子4 (PF4) 及其在疾病中的多重作用
Zhiyan Liu1, Longtu Li2, Hanxu Zhang2
1Department of Pharmacy, Peking University First Hospital, China; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China; Institute of Clinical Pharmacology, Peking University First Hospital, China.
Blood reviews
|November 26, 2023
概括
血小板因子4 (PF4) 与肝素诱导的血小板缩症 (HIT) 和COVID-19疫苗诱导的免疫血小板血小板缩症 (VITT) 有关. 了解PF4的理解
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血小板因子4 (PF4) 是一种参与免疫反应的化学因子.
- PF4-氨酸复合体可以触发IgG抗体,导致氨酸诱导的血小板缩 (HIT).
- PF4在COVID-19疫苗诱导的免疫血栓性血栓性缺血症 (VITT) 中的作用凸显了其更广泛的临床意义.
研究的目的:
- 审查PF4的特性和生物功能.
- 总结一下PF4介导的信号通路.
- 讨论PF4在各种疾病中的多样性作用.
主要方法:
- 关于PF4参与血栓形成和其他疾病的文献综述.
- 分析PF4与带电分子的静电相互作用.
- 探索PF4的信号通路和药理作用.
主要成果:
- PF4在HIT和VITT中发挥着关键作用,涉及静电相互作用.
- 新出现的证据表明,PF4参与了造血抑制,血管生成,凝血,炎症和抗瘤活性.
- PF4表现出热性质,为向药物开发带来了挑战.
结论:
- 由于PF4的多面性作用,需要对其机制进行进一步的研究.
- 了解PF4通路可以加速针对PF4相关疾病的向疗法的开发.
- 针对PF4的治疗方法的临床转化需要解决当前的发展挑战.
相关概念视频
Structure and Function of Platelets
1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
711
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
711
Formation of the Platelet Plug
6.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.4K
Clot Retraction and Fibrinolysis
6.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.2K
Disorders of Hemostasis
926
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
926
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
532
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
532


